⌕
Gilead Sciences · GILD · Nasdaq
Tenet 37 · Weak
Compare
$167.58−0.30%At closeTenet 37 · Weak
$167.58−0.50 (−0.30%)
At close: Nov 16, 2026, 4:00 PM ET· Nasdaq · USD
$169.02+1.44 (+0.86%)
After hours: Nov 16, 2026, 7:41 PM ET

Gilead Sciences (GILD) Stock

Gilead Sciences (GILD) closed at $167.58 on Nov 16, 2026; its Tenet Score is 37 of 100 against 313 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

5 figures withheld by our checks. Each blank figure names its reason.

Key stats

Previous close
$167.58
Nov 16, 2026
Market cap
$208.5B
share price × the latest quarter's diluted weighted-average share count (vendor)
Dividend yield
1.93%
past year's regular dividends ÷ price
52-week range
116.88 – 176.58
low → high · as of close, Nov 13, 2026
Tenet Score
37/100
Weak · 313 Healthcare peers

Industry: Drugs

Gilead Sciences, Inc. scores 37/100. Weak. Financial health is the soft spot versus 313 Healthcare peers.

Tenet Score · vs sector

n=313
37/ 100
Weak
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
29
Quality
53
Health
10
Growth
58

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
ValueFQualityCHealthFGrowthCMomentumB
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/E
—
Not meaningful: the company made a loss.
P/B
16.0×
price to book value
P/S
6.7×
price to fiscal 2025 sales
ROE
−22%
return on equity
Operating margin
34.0%
fiscal 2025, before interest and tax
Net margin
−12.5%
of revenue kept
Current ratio
1.38
current assets to liabilities
Net debt / EBITDA
43.8×
leverage, net of cash
EPS CAGR 5y
—
This growth figure starts in a period outside the history your plan includes.

The whole report, at a glance · every card is a live peek, click any to open the section

About Gilead Sciences, Inc.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Co…

Composite computed Nov 13, 2026 · peer basis: Healthcare (n=313) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 488 US ETFs · top wrappers by weightSee all ETFs holding GILD →

Similar-sized companies in Drugs

The 10 companies in this industry closest in market cap, as of Nov 13, 2026.

CompanyTenet ScoreMarket cap
Merck & Co IncMRK41$364.3B
Novartis AGNVS56$306.3B
AMGEN Inc.AMGN47$251.9B
Novo NordiskNVO63$185.9B
Pfizer Inc.PFE50$164.7B
Vertex Pharmaceuticals, Inc.VRTX55$136.6B
Bristol-Myers Squibb Co.BMY51$129.7B
GSK PlcGSK51$108.9B
Regeneron Pharmaceuticals, Inc.REGN64$98.8B
Moderna IncMRNA33$90.4B

Compare Gilead Sciences with

What sector and industry is Gilead Sciences in?

Gilead Sciences is in the Healthcare sector and the Drugs industry.

What is Gilead Sciences' Tenet Score?

Gilead Sciences' Tenet Score is 37 out of 100, ranked against 313 Healthcare peers as of Nov 13, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.